Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peposertib with Chemotherapy in SCLC
NCT03116971Phase 1Terminated
- Sponsor
- EMD Serono
- Start
- May 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 1, randomised, double-blind trial of peposertib in small cell lung cancer (SCLC) (2 arms), sponsored by EMD Serono. Primary endpoints: Dose-Limiting Toxicity at 21 days, Recommended Phase II Dose at 11 months and 1 more. Started May 2017; status: terminated.
02
Drugs
peposertib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03116971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03116971.